H.C. Wainwright raised the firm’s price target on Enliven (ELVN) to $48 from $40 and keeps a Buy rating on the shares after the company presented updated results from the Phase 1a/1b ENABLE trial at EHA 2025. Following the presentation at the medical meeting, the firm contends that ELVN-001 could become “the go-to agent” in chronic myelogenous leukemia.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer?
- Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study
- Enliven Therapeutics Appoints New Directors at Annual Meeting
- Short Report: Short interest in residential solar heats up again
- Enliven price target raised to $52 from $40 at Baird